1 Great Valley Parkway
Suite 24
Malvern, PA 19355
United States
484 320 2930
https://www.telabio.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 227
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Antony Koblish | Co-founder, President, CEO & Director | 1.03M | N/D | 1966 |
Mr. Roberto E. Cuca J.D. | CFO & COO | 674.78k | N/D | 1968 |
Mr. Paul Talmo | Chief Technology Officer | 595.67k | N/D | 1972 |
Ms. Megan Smeykal | VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer | N/D | N/D | 1976 |
Mr. D. Taylor Ocasio | General Counsel & Corporate Secretary | N/D | N/D | N/D |
Ms. Jennifer Lou Armstrong | Senior Vice President of Human Resources | N/D | N/D | 1970 |
Mr. Gregory A. Firestone | Chief Commercial Officer | N/D | N/D | 1959 |
Mr. Michael Leonard | Senior Vice President of Technical Operations | N/D | N/D | N/D |
Mr. Peter C. Murphy | Chief Commercial Officer | 542.34k | N/D | 1973 |
Louisa Smith | Investor Relations Contact Officer | N/D | N/D | N/D |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
La calificación ISS Governance QuickScore de TELA Bio, Inc. a partir del 1 de septiembre de 2024 es 9. Las puntuaciones principales son Auditoría: 4; Junta: 5; Derechos del accionista: 8; Compensación: 10.